Aesthetic Injectable Devices is expected to reach US$ 17.58 Billion by 2031

Botulinum Toxin Segment based on Product to Bolster Aesthetic Injectable Devices Market Growth  

According to our new research study on "Aesthetic Injectable Devices Market Forecast to 2031 – Global Analysis – by Product, Device Type, Application, Age Group, Gender, and End User," the market was valued at US$ 10.31 billion in 2024 and is projected to reach US$ 17.58 billion by 2031; it is anticipated to record a CAGR of 8.1% from 2025 to 2031. The report emphasizes the aesthetic injectable devices market trends, along with drivers and deterrents affecting the market growth. The burgeoning demand for minimally invasive cosmetic procedures, soaring aging population, and desire for youthful appearance are contributing to the growing aesthetic injectable devices market size. However, the high cost of treatments with recurring needs hampers market growth. Further, the regenerative aesthetic treatments are expected to emerge as a new market trend in the coming years.

Burgeoning Demand for Non-Invasive Cosmetic Procedures Bolsters Aesthetic Injectable Devices Market Growth

People prefer treatments such as aesthetic injectables over traditional surgical procedures because they offer lower risks, quicker recovery times, and visible results without the need for major surgery.  Aesthetic injectables, such as botulinum toxin (Botox) injections and hyaluronic acid fillers, address skin concerns such as wrinkles, fine lines, facial volume loss, and contour asymmetries. The number of non-surgical aesthetic procedures performed globally is increasing gradually, as the appearance of the skin is considered an important factor in well-being and health. Botox, dermal fillers, and other neurotoxins are widely used for wrinkle reduction, lip enhancement, and facial contouring.

Aesthetic Injectable Devices Market Share, by Region, 2024 (%)

Source: The Insight Partners Analysis

A growth in non-surgical cosmetic procedures is witnessed worldwide, with surging demand among people to address issues related to wrinkles, fine lines, etc. The International Society of Aesthetic Plastic Surgery (ISAPS) defines non-surgical cosmetic procedures as aesthetic treatments performed without making incisions to reach the deeper layers of tissue. According to the ISAPS Global Survey on Aesthetic/Cosmetic Procedures, 19.1 million non-surgical procedures were performed in 2023. The most popular non-surgical procedures included hyaluronic acid, botulinum toxin, hair removal, non-surgical skin tightening, and non-surgical fat reduction. Botulinum toxin is a commonly performed non-surgical procedure for men and women across all age groups, with plastic surgeons carrying out 8.8 million treatments worldwide in 2023. Hyaluronic acid procedures ranked second, rising by 29% to a total of 5.5 million procedures. In Brazil, the total number of non-surgical cosmetic procedures performed increased from 0.97 million in 2022 to 1.19 million in 2023. There was an increase of approximately 225,000 procedures from 2022 to 2023, representing a 23.2% rise in non-surgical cosmetic procedures in Brazil. This trend is common among millennials and Gen Z, who favor procedures with natural-looking outcomes and short recovery times.

With the ever-increasing popularity of non-surgical enhancement and an increasing number of patients, the demand for aesthetic injectable devices is rising. Thus, the surge in the adoption of such aesthetic procedures fuels the aesthetic injectable devices market growth.

Scope of Aesthetic Injectable Devices Market Report:

The aesthetic injectable devices market analysis has been carried out by considering the following segments: product, device type, application, age group, gender, end user, and geography. 

Based on product, the aesthetic injectable devices market is segmented into dermal fillers, botulinum toxin, and others. The dermal fillers segment is classified into calcium hydroxylapatite, hyaluronic acid, collagen, poly-l-lactic acid, polmethylmethacrylate, Fat Fillers, and others. The botulinum toxin segment held the largest share of the market in 2024. Botulinum toxin is widely used in aesthetic medicine due to its versatility, particularly for treating dynamic wrinkles and fine lines. It acts by temporarily relaxing the facial muscles responsible for expressions. Botulinum toxin type A (BoNTA) is a purified neurotoxic protein derived from bacteria that inhibits muscle contractions. It is used to reduce facial wrinkles and treat common signs of aging, such as frown lines, forehead lines, and neck bands. As global demand for aesthetic treatments continues to rise, Botox has become an essential solution for age-related cosmetic concerns. Botox—the most recognized brand in this field—has earned trust and recognition among practitioners and patients. Its popularity is driven by its effectiveness in managing medical conditions and the increasing disposable income of a growing global population. Its long-standing presence and strong marketing strategies have played a role in securing its foremost place in the market.

According to statistics from the International Society of Aesthetic Plastic Surgery (ISAPS), botulinum toxin injections continue to be the most commonly performed non-surgical procedure among men and women across all age groups. Plastic surgeons worldwide carried out 8.8 million of these procedures in 2023. More than 4.7 million botulinum toxin type A procedures were performed in 2024-2025.

Recent approvals underscore ongoing product evolution. In July 2024, Merz Aesthetics received US FDA approval for XEOMIN (incobotulinumtoxinA), the first and only neurotoxin authorized for the treatment of forehead lines, frown lines, and crow’s feet.

By device type, the aesthetic injectable devices market is categorized into microcannulas, pre‑filled syringes, mesotherapy guns, and others. The pre‑filled syringes segment dominated the market in 2024. Pre‑filled syringes (PFS) are hermetically sealed single-use injection devices. They are pre‑loaded with a precise dose of aesthetic products such as botulinum toxin, dermal fillers (e.g., hyaluronic acid), and growth factors. Widely used in clinical and at-home settings, they simplify administration, reduce dosing errors, and enhance safety than traditional vial‑and‑syringe systems. Manufacturers are enhancing PFS for aesthetic use. SCHOTT TOPPAC cosmetic prefilled syringes are specifically engineered to simplify cosmetic treatments and enhance comfort for healthcare providers and patients. Crafted from advanced Cyclic Olefin Copolymer (COC), the syringe provides a three-year shelf life, ensuring long-term drug stability, with a shape and design optimized for hyaluronic acid injections. The COC material used in this cosmetic syringe is inert and compatible with various formulations. The syringes feature a reduced inner diameter, enabling lower extrusion forces for smoother delivery and more precise dosing. An integrated Luer Lock ensures secure and reliable needle attachment.

Based on application, the aesthetic injectable devices market is segmented into facial line correction, face lift, lip treatment, anti-ageing and wrinkle treatment, acne and scar treatment, stretch marks, and others. The facial line correction segment held the largest share of the market in 2024. As people age, the natural production of collagen and elastin declines, leading to a loss of skin elasticity and firmness. Injectable treatments for facial lines help restore a more youthful look, making them especially appealing to the aging population. These injectables offer a non-invasive alternative to traditional surgical procedures, with reduced recovery time and minimal discomfort. Dermal fillers can be used to fill in facial lines and restore volume to the face, giving a smoother and more youthful appearance. Common areas for facial line correction treatment include nasolabial folds (smile lines), marionette lines, and vertical lip lines. Different fillers are available for various depths and lines, allowing for a customized treatment plan.

Non-invasive cosmetic procedures—such as Botox and dermal fillers— reduce the appearance of facial lines and wrinkles.  Botulinum toxins and hyaluronic acid-based dermal fillers are used to address dynamic and static wrinkles such as crow’s feet, forehead furrows, frown lines, and nasolabial folds. As per the article “26 Facts About Cosmetic Injectables,” Restylane (a line of hyaluronic acid fillers) has been used in more than 28 million treatments globally to help smooth out wrinkles and fine lines.

The innovations in injectable formulations and delivery methods are improving safety and treatment outcomes, boosting the popularity of facial line correction procedures. Collagen stimulators such as PLLA (Sculptra) and long-lasting PMMA microsphere fillers (Artefill) are gaining traction. Sculptra offers natural collagen benefits with effects lasting up to two years. Artefill provides semi-permanent correction, offering structural longevity for up to five to ten years.

By age group, the aesthetic injectable devices market is categorized into Up to 30, 31-40, 41-50, 51-60, and More Than 60. The 31-40 segment dominated the market in 2024. Adults aged 31–45 commonly seek wrinkle reduction and facial contouring, especially around the mid-30s when collagen production starts to decrease. ASPS’s 2023 data shows that approximately 15.8 million injectable procedures were performed in 2023, with ~9.5 million Botox (neuromodulators) and 5.3 million hyaluronic‑acid filler procedures. As per the article “The Most Surprising New Botox and Filler Trends,” out of all the people getting hyaluronic acid fillers in their lips, cheeks, and under-eye hollows, young millennials (ages 30-39) grew at the fastest rate, with a 9% rise over 2022. This direction is accompanied by evolving consumer preferences, as this group leans toward hyaluronic acid fillers for their safety, biocompatibility, and flexibility in customization, as opposed to collagen-based fillers. Volume loss, early photodamage, or undermined collagen production often surface in the late 30s, prompting patients to seek treatments that restore youthful contours or treat nasolabial folds, tear troughs, and early jowling.

Per gender, the aesthetic injectable devices market is bifurcated into female and male. The female segment dominated the market in 2024. Women between 30 and 50 years undergo treatments for anti-aging, facial renewal, and skin hydration. Due to the rising awareness through social media platforms and celebrity endorsements, these treatments are gaining popularity among women. As per the International Society of Aesthetic Plastic Surgery, in 2023, 29,920,828 women underwent non-surgical cosmetic procedures globally. As per Botox Usage Statistics 2023, women received nearly 7.9 million Botox treatments out of over 9.2 million globally in 2022. Hyaluronic‑acid fillers highlight similar trends, with approximately 86.8 % of filler users being female. The majority of these recipients fall within the 35–50 age group, which led all segments that year with over 4.4 million Botox sessions.

This strong female tilt surpasses mere anti-aging, as women utilize injectables for facial contouring, lip augmentation, and skin rejuvenation. The broader “Instagram Face” trend, featuring full lips, high cheekbones, and poreless skin, has normalized these procedures in women, linking social media influence to rising demand. Among women aged 20–29, the “Baby Botox” trend has gain traction for preventative wrinkle control, reinforcing early adoption among younger cohorts. According to the article “Is luxury aesthetic medicine beauty’s next boom in China?” published in May 2021, in China, 90 % of aesthetic medicine consumers were women, with an average user age of just 24.45. It highlights growing acceptance among younger women in Asia-Pacific.

By end user, the aesthetic injectable devices market is categorized into medical spas, dermatology clinics, hospitals, and others. The dermatology clinics segment dominated the market in 2024. The dermatology clinics, led by board-certified dermatologists, deliver injectable treatments such as botulinum toxin and dermal fillers. They deliver these treatments due to their medical expertise, access to advanced infrastructure, and high safety standards. Patients having specific skin or hair conditions require expert evaluation and management. Dermatologists help diagnose and treat issues such as acne and aging skin. Dermal filler treatments offered in dermatology clinics address these specific concerns, with customized formulations designed to target the underlying causes of skin problems. The expertise and specialized knowledge of dermatologists in diagnosing and treating skin conditions stand as one of the primary advantages of receiving aesthetic injectable treatments at dermatology clinics.

The rising prevalence of acne and scars, coupled with an increasing number of clinics offering dermal filler treatment, is propelling the number of patients visiting dermatology clinics. Dermatologists provide a full-service clinical setting—from comprehensive skin assessments to injectable delivery—ensuring safety and continuity when dealing with delicate facial anatomy and potential complications.

Real-world evidence highlights how skincare giants are capitalizing on dermatology clinics to drive injectable adoption. For instance, Galderma reports that most of the US dermatology practices use Dysport, with products such as Sculptra gaining traction.

Aesthetic Injectable Devices Market Analysis: Based on Geography

The geographic scope of the aesthetic injectable devices market includes the assessment of the market performance in North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), South & Central America (Brazil, Argentina, and the Rest of South & Central America), and the Middle East & Africa (South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa).    

The International Society of Aesthetic Plastic Surgery (ISAPS), the World Health Organization (WHO), the American Society of Plastic Surgeons, and the Canadian Dermatology Association are among the primary and secondary sources referred to while preparing the aesthetic injectable devices market report.  

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com